A Novel CYP2E1 Inhibitor, 4-Methyl-5-Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and...

Area of Science:

• Metabolic disease research
• Mitochondrial biology
• Pharmacology

Background:

• Obesity is a global health crisis linked to inflammation and poor mitochondrial function.
• Cytochrome P450 2E1 (CYP2E1) is involved in oxidative stress, but its role in obesity-related adipocyte dysfunction is unclear.

Purpose of the Study:

• To investigate the role of CYP2E1 in obesity.
• To assess the therapeutic potential of the selective CYP2E1 inhibitor, Q11, in obesity.

Main Methods:

• Utilized high-fat diet-induced obese mouse models.
• Administered the selective CYP2E1 inhibitor Q11.
• Assessed body weight, hepatic steatosis, inflammation, and mitochondrial function (oxygen consumption, membrane potential, biogenesis, fusion).
• Analyzed the AMP-activated protein kinase/peroxisome proliferator-activated receptor-gamma coactivator 1-alpha pathway.

Main Results:

• Obese mice showed increased CYP2E1 expression and activity, correlating with adiposity and mitochondrial dysfunction.
• Q11 treatment reduced body weight gain, hepatic lipid accumulation, and inflammation without affecting appetite.
• Q11 restored mitochondrial integrity, enhanced oxygen consumption, promoted biogenesis, and improved fusion dynamics.
• Q11 activated the AMPK/PGC-1α pathway.

Conclusions:

• CYP2E1 is a key regulator of obesity-associated metabolic dysfunction.
• Q11 demonstrates therapeutic potential for obesity by reducing inflammation and improving mitochondrial homeostasis.
• Targeting CYP2E1 offers a promising strategy for treating obesity and related metabolic disorders.